60 DEGREES PHARMACEUTICALS LLC (SXTP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.94-7.18%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · SXTP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -83.4% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 22.1% |
Growth built into the price is above our model estimate.
The price assumes 105.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
SXTP — litigation filed
Dated 2026-10-23
Regulation FD Disclosure On October 23, 2026, the Company updated its investor presentation, which it intends to use from time to time in meetings with investors, analysts and other members of the investment community. A copy of the updated investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section…
Why it matters: Steady revenue growth shows ARAKODA is accepted in the market. This helps the company become profitable.
Supportive ifQ3 net product revenue exceeds $416k, maintaining over 100% growth YoY.
Worry ifQ3 revenue growth falls below 100% YoY.
Why it matters: This submission is key for growing the product's market and revenue.
Supportive ifThe company files the NDA for tafenoquine earlier than planned.
Worry ifThe company delays the NDA submission beyond Q1 2028.
Why it matters: More revenue from ARAKODA shows strong demand and helps the path to making money.
Supportive ifQ3 2026 net product revenue exceeds $250k, showing continued growth.
Worry ifQ3 2026 net product revenue falls below $200k, indicating weak demand.
Why it matters: The unblinding will show if tafenoquine works for treating babesiosis. This is key for FDA approval.
Supportive ifThe hospital study shows good results. There is clear clinical improvement.
Worry ifThe study does not meet its main goal or shows no real improvement.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$355 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $1,247 loss on $10,000 · 12.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,577 loss on $10,000 · 85.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Revenue trends will show if the company is on track for profits by 2028.
Watch forQ3 revenue shows growth compared to the previous quarter.
Also watch forQ3 revenue falls again compared to the last quarter.
Why it matters: More directors could help governance and boost investor trust.
Supportive ifA new director has been added to the Board.
Worry ifNo new directors or governance changes have been announced.
Why it matters: The results will indicate if tafenoquine can expand its use beyond malaria. This could drive future revenue.
Supportive ifThe tafenoquine trial for babesiosis has good early results. It shows it works and is safe.
Worry ifThe tafenoquine trial for babesiosis has bad early results. It may not work or be safe.
Why it matters: The results will show progress towards the NDA submission for babesiosis.
Watch forThe analysis shows good results. This is a positive sign for development.
Also watch forThe analysis shows bad results. This stops further development.
Why it matters: Earnings results will show how the company is doing financially.
Watch forThe earnings report shows more revenue or fewer losses than before.
Also watch forThe earnings report shows ongoing losses or falling revenue.
Why it matters: FDA feedback can show which evidence path the company can use and what data it still needs.
Watch forThe company reports FDA agreement on a filing path for babesiosis. This includes whether NAT negativity can support a claim of no relapse.
Also watch forThe company says FDA will not accept the proposed evidence or wants a new key study before filing.
Why it matters: This feedback will help plan the submission for tafenoquine in babesiosis. Good feedback could speed up approval.
Supportive ifFDA gives positive feedback on the plan for tafenoquine.
Worry ifFDA has major concerns about the data or the plan.
Why it matters: FDA feedback will show how likely tafenoquine is to get approved for babesiosis. This could affect future money made.
Supportive ifThe FDA gives good feedback on the babesiosis sNDA submission.
Worry ifThe FDA issues a complete response letter or negative feedback on the submission.